Symbiotec Pharmalab IPO Day 2 Subscription Status: Issue Subscribed 1.14x, NII Demand Stays Ahead

Mumbai, August 25: The Symbiotec Pharmalab IPO has picked up pace on the second day of bidding, with the ₹1,757 crore issue moving past the full-subscription mark during the morning session. As of 10:49 AM on August 25, the IPO had been subscribed 1.14 times, with non-institutional investors continuing to show the strongest response among the main investor categories.

Investors had put in bids for 1,42,65,135 shares, against 1,24,60,533 shares offered to the public. At the upper end of the IPO’s price band, the bids were worth around ₹1,409.40 crore. The number of applications had reached 4,49,702 by the time of the update.

The NII portion is currently setting the pace. It has been subscribed 1.49 times, after receiving bids for 39,56,400 shares against the 26,62,955 shares reserved for the category.

Retail investors have also pushed their allocation comfortably above the one-time mark. The retail portion stood at 1.33 times, with bids for 82,38,795 shares compared with 62,13,562 shares available.

Institutional participation is moving at a slower pace. The QIB portion, excluding anchor investors, was subscribed 0.56 times. Employee investors, on the other hand, have shown stronger interest, with their reserved portion subscribed 2.05 times.

There is a clear difference within the NII category as well. The sNII segment was subscribed 2.25 times, while the bNII portion stood at 1.10 times.

Symbiotec Pharmalab’s IPO comprises a fresh issue of 15,21,261 shares worth up to ₹150 crore and an offer for sale of 1,62,65,181 shares aggregating up to ₹1,607 crore. Together, the issue size comes to around ₹1,757 crore.

The Symbiotec Pharmalab IPO has been priced in the ₹938 to ₹988 per share range and will remain open for subscription through August 27, 2026. Eligible employees also get a ₹90 discount on the issue price.

Symbiotec Pharmalab IPO Subscription Status Day 2 (As Of 10:49 AM)

The latest figures show that the IPO has crossed the overall subscription mark, although investor interest remains uneven across categories:

• Overall: 1.14x
• Retail: 1.33x
• NII: 1.49x
• bNII (> ₹10L): 1.10x
• sNII (< ₹10L): 2.25x
• QIB (Ex-Anchor): 0.56x
• Employees: 2.05x
• Total Applications: 4,49,702

NII investors are currently providing the biggest push to the public issue, with their portion subscribed almost one and a half times. The smaller-ticket sNII category has been particularly active, already reaching 2.25 times subscription.

Retail demand has also held up well. At 1.33 times, the retail book has received more bids than the shares set aside for the category.

The institutional book is telling a different story for now. QIB subscription is still at 0.56 times, meaning the category is yet to be fully covered. With the issue remaining open, institutional participation could become an important factor in determining where the final subscription number lands.

Employees have also shown healthy interest, with their portion subscribed 2.05 times.

Day-Wise Subscription Trend

The IPO had a fairly measured start on Day 1, ending the first session at 0.85 times subscription. The second day’s bidding has pushed the issue into fully subscribed territory, taking the overall figure to 1.14 times by the latest update.

The first day was largely driven by NII, retail and employee participation. Retail investors just managed to cover their quota at 1.01 times, while NII demand was already at 1.10 times.

Day 2 has brought a broader improvement. NII subscription has risen from 1.10 times to 1.49 times, while retail demand has moved from 1.01 times to 1.33 times.

The sNII category has continued to stand out, climbing from 1.66 times on Day 1 to 2.25 times. Employee subscription has also increased from 1.65 times to 2.05 times.

QIB participation has improved from 0.37 times to 0.56 times, but it remains the only major category below full subscription.

Overall, the IPO has gone from 0.85 times at the end of Day 1 to 1.14 times on Day 2. There is still plenty of bidding time left, so the final picture could look quite different by the time the issue closes.

IPO Details

• Issue Size: ₹1,757 crore
• Fresh Issue: 15,21,261 equity shares aggregating up to ₹150 crore
• Offer For Sale: 1,62,65,181 equity shares aggregating up to ₹1,607 crore
• Price Band: ₹938 to ₹988 per share
• Issue Price: ₹988 per share
• Lot Size: 15 shares
• Minimum Retail Investment: ₹14,820 (15 shares)
• Minimum S-HNI Investment: ₹2,07,480 (210 shares)
• Listing Exchange: BSE and NSE
• Issue Type: Bookbuilding IPO
• Employee Reservation: 33,408 shares
• Employee Discount: ₹90 per share

A retail investor needs to bid for at least 15 shares, or one lot. At the upper price of ₹988, that works out to a minimum investment of ₹14,820.

For S-HNI investors, the minimum application is 210 shares, equivalent to 14 lots. At the issue price, this requires ₹2,07,480.

The company has also kept aside 33,408 shares for employees, with eligible employees getting a ₹90 discount on the issue price.

Key Dates

• IPO Opens: August 24, 2026
• IPO Closes: August 27, 2026
• Tentative Allotment: August 28, 2026
• Refund Initiation: August 31, 2026
• Shares Credited To Demat Accounts: August 31, 2026
• Tentative Listing: September 1, 2026

About Symbiotec Pharmalab Ltd.

Symbiotec Pharmalab Limited, incorporated in 2002, is a pharmaceutical and biotechnology company focused on active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products.

The company serves customers in India as well as overseas markets, including both regulated and emerging regions. Its operations have expanded considerably over the years, moving beyond its early focus on steroidal hormone APIs to a broader, backward-integrated manufacturing setup.

Symbiotec has more than three decades of experience in the industry and has built a presence across several international markets. Its regulatory approvals and certifications include those from the US Food and Drug Administration, European Union Good Manufacturing Practices and South Korea’s Ministry of Food and Drug Safety, along with other global regulatory bodies.

Conclusion

The Symbiotec Pharmalab IPO has made a better showing on Day 2, moving from 0.85 times subscription at the end of August 24 to 1.14 times by 10:49 AM on August 25. NII investors are currently leading the main categories at 1.49 times, with retail investors at 1.33 times.

The strongest response within the NII book is coming from the sNII segment, which has already reached 2.25 times. Employee participation is also solid at 2.05 times, while QIB subscription remains relatively subdued at 0.56 times.

The issue will stay open until August 27, so the subscription numbers can still move substantially before bidding closes. The basis of allotment is expected on August 28, followed by refunds and demat credit on August 31. Symbiotec Pharmalab shares are tentatively scheduled to list on the BSE and NSE on September 1, 2026.

Source:

• https://www.nseindia.com/market-data/issue-information?symbol=SYMBIOTEC&series=EQ&type=Active